APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3934-3945

  Cagnetta, Antonia ^a,b   Caffa, Irene ^a   Acharya, Chirag ^b   Soncini, Debora ^a   Acharya, Prakrati ^c   Adamia, Sophia ^b   Pierri, Ivana ^a   Bergamaschi, Micaela ^a   Garuti, Anna ^a   Fraternali, Giulio ^d   Mastracci, Luca ^d   Provenzani, Alessandro ^e   Zucal, Chiara ^a   Damonte, Gianluca ^a   Salis, Annalisa ^a   Montecucco, Fabrizio ^f   Patrone, Franco ^a   Ballestrero, Alberto ^a   Bruzzone, Santina ^a   Gobbi, Marco ^a   Nencioni, Alessio ^a   Cea, Michele ^a,b   more..

^a UNIVERSITY OF GENOA   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF TRENTO   (Italy)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CELL MARKER; CYCLOSPORIN A; DAPORINAD; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID; PGP 4008; UNCLASSIFIED DRUG; VERAPAMIL; ACRYLAMIDE DERIVATIVE; CYCLOSPORIN; IMMUNOGLOBULIN HEAVY CHAIN; MULTIDRUG RESISTANCE PROTEIN; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; PIPERIDINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; CANCER PROGNOSIS; CELL KILLING; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL SURVIVAL; CHROMOSOME ABERRATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; LEUKEMIA; MALE; METABOLISM; MIDDLE AGED; MITOCHONDRION; MORTALITY; MUTATION; PATHOLOGY; PRIMARY CELL CULTURE; PROGNOSIS; TUMOR CELL CULTURE; TUMOR CELL LINE; UNFOLDED PROTEIN RESPONSE;

ACRYLAMIDES; ADENOSINE TRIPHOSPHATE; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMOSOME ABERRATIONS; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MITOCHONDRIA; MUTATION; NAD; NEOPLASM STAGING; NIACIN; NIACINAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; P-GLYCOPROTEINS; PIPERIDINES; PRIMARY CELL CULTURE; PROGNOSIS; TUMOR CELLS, CULTURED; UNFOLDED PROTEIN RESPONSE;

EID: 84942885599     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3023     Document Type: Article

References (58)

1. + metabolism in health and disease. Trends Biochem Sci 2007;32:12-9.
2. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63: 7436-42.
3. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by NAMPT/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70.
4. +salvage pathway induces autophagy in multiplemyeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012;120:3519-29.
5. Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, Li HJ, et al. Overexpression of NAMPT in gastric cancer and chemopotentiating effects of the NAMPT inhibitor FK866 in combination with fluorouracil. Oncol Rep 2011;26: 1251-7.
6. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. NAMPT overexpression in prostatecancer and its contribution to tumor cell survival and stress response. Oncogene 2011;30:907-21.
7. Gehrke I, Bouchard ED, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, et al. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clin Cancer Res 2014;20:4861-72.
8. + precursor vitamins in human nutrition. Annu Rev Nutr 2008;28:115-30.
9. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 2006; 13:582-8.
10. Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, et al. APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood 2009;113:6035-7.
11. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009;113:3276-86.
12. Zoppoli G, Cea M, Soncini D, Fruscione F, Rudner J, Moran E, et al. Potent synergistic interaction between the NAMPT inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 2010;38:979-88.
13. Chan M, Gravel M, Bramoulle A, Bridon G, Avizonis D, Shore GC, et al. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res 2014;74:5948-54.
14. Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nussler V, Hasmann M. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006;11:313-21.
15. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008;181:4685-95.
16. Ginet V, Puyal J, Rummel C, Aubry D, Breton C, Cloux AJ, et al. A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis. Autophagy 2014;10:603-17.
17. Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, et al. Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity. Blood 2013;122:1243-55.
18. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 2007;55:1-15.
19. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
20. Sugawara I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathol Jpn 1990;40: 545-53.
21. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99.
22. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004;104: 1940-51.
23. Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin, and cytarabine. Haematologica 2004;89:782-90.
24. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 2009;15:3574-82.
25. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was Pgp nothing but the first head of the Hydra? Leukemia 2007;21:1172-6.
26. Malayeri R, Filipits M, Suchomel RW, Zochbauer S, Lechner K, Pirker R. Multidrug resistance in leukemias and its reversal. Leuk Lymphoma 1996;23:451-8.
27. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993;82:1288-99.
28. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005;5:78.
29. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995;34:235-41.
30. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: cancer and leukemia group Bstudy 19808. Blood 2010;116:1413-21.
31. Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, et al. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem 2014;289:34189-204.
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
33. Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009;15:151-8.
34. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
35. Cea M, Cagnetta A, Patrone F, Nencioni A, Gobbi M, Anderson KC. Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy 2013;9:410-2.
36. + depletion in activated T lymphocytes through NAMPT inhibition reduces demyelination and disability in EAE. PLoS ONE 2009;4:e7897.
37. Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS ONE 2011;6:e22739.
38. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980;1:327-9.
39. Wang P, Heitman J. The cyclophilins. Genome Biol 2005;6:226.
40. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-7.
41. Hall AG, Cattan AR. Drug resistance mechanisms in leukaemia. Baillieres Clin Haematol 1991;4:655-81.
42. Verweij J, Herweijer H, Oosterom R, van der Burg ME, Planting AS, Seynaeve C, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin - A in an attempt to reverse multidrug resistance. Br J Cancer 1991;64:361-4.
43. Fridborg H, Jonsson B, Nygren P, Csoka K, Nilsson K, Oberg G, et al. Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. Br J Cancer 1994;70: 11-7.
44. Dalton WS, Salmon SE. Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol Oncol Clin North Am 1992;6: 383-93.
45. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
46. + levels dictate cell survival. Cell 2007;130: 1095-107.
47. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014;14: 581-97.
48. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008;8: 663-74.
49. Yoshida H. ER stress and diseases. FEBS J 2007;274:630-58.
50. Dantuma NP, Lindsten K. Stressing the ubiquitin-proteasome system. Cardiovasc Res 2010;85:263-71.
51. Ciechomska IA, Gabrusiewicz K, Szczepankiewicz AA, Kaminska B. Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporin a-induced cell death. Oncogene 2013;32: 1518-29.
52. Koh IU, Lim JH, Joe MK, Kim WH, Jung MH, Yoon JB, et al. AdipoR2 is transcriptionally regulated by ER stress-inducible ATF3 in HepG2 human hepatocyte cells. FEBS J 2010;277:2304-17.
53. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97:9902-6.
54. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009;29:5872-88.
55. Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B, Loser R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res 2002;62:1057-62.
56. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008; 112:4193-201.
57. Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 2011;25:1639-45.
58. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-30.